Kenacort-A

Triamcinolone Acetonide, the active ingredient in Kenacort‑A, is a glucocorticoid corticosteroid presented as an injectable solution for intra‑articular and intradermal administration. It is used to reduce inflammation in joint disorders such as arthritis and in various dermatologic inflammatory conditions, primarily in adult patients.

GNH USA supplies Kenacort‑A as a licensed, GDP‑compliant product to hospitals, pharmacies and clinics worldwide, meeting EU market standards and supporting international procurement for a range of therapeutic needs, including rheumatology and dermatology services, and ensuring consistent quality across shipments.

Kenacort‑A (triamcinolone acetonide) is a glucocorticoid used to manage inflammatory conditions of the musculoskeletal and skin systems. - Arthritis: reduces joint inflammation and pain, improving mobility. - Dermatologic inflammatory conditions: diminishes skin swelling, redness, and itching. - Synovitis: decreases inflammation of the synovial membrane, enhancing joint function.

Kenacort‑A may cause a range of adverse reactions. Monitoring and patient counseling are essential.

Common Side Effects: - Pain or tenderness at the injection site. - Local bruising or discoloration. - Transient increase in blood glucose levels. - Mild hypertension. - Temporary skin thinning at the injection area. - Headache.

Serious or Rare Side Effects: - Severe infection at the injection site or systemic infection. - Adrenal suppression leading to cortisol deficiency. - Osteonecrosis of the jaw or other bones. - Anaphylactic or severe allergic reaction. - Significant hyperglycemia requiring medical intervention. - Tissue necrosis or ulceration.

Before using Kenacort‑A, clinicians should consider several safety measures. - Assess infection risk: avoid injection in patients with active infections. - Monitor blood glucose: patients with diabetes may experience hyperglycemia. - Evaluate bone health: prolonged use can affect bone density. - Use lowest effective dose: limit systemic exposure. - Avoid in uncontrolled hypertension: monitor blood pressure regularly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Kenacort‑A can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Systemic CYP3A4 inhibitors (e.g., ketoconazole) may increase steroid levels. - Live vaccines: risk of reduced vaccine efficacy and infection. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal irritation. - Diuretics: can exacerbate electrolyte imbalances. - Antidiabetic agents: may require dose adjustments due to altered glucose control.